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References 12 iv Tables   Table 1  Cohort Characteristics  15   Table 2 Multivariate Analysis: Significant Predictors of IAPBI Use 16 Table 3 Use B-06 reported in 1985 that survival after breast conserving surgery (BCS) and whole breast radiation therapy (WBRT) was equivalent to mastectomy (1) . The National
List of
Institute of Health then released a consensus statement in 1990 stating that BCS and WBRT was the preferred treatment for early stage breast cancer (2) . As a result, the practice patterns in the United States changed dramatically, and BCS rates markedly increased (3) . The benefit of WBRT has been established by several randomized trials that have demonstrated that local recurrence rates are higher in patients treated with BCS alone compared to BCS plus WBRT (1, (4) (5) . Our aim in the present study was to determine the use of implantable APBI (IAPBI) in the United States using a population-based dataset and to determine the patient and tumor factors associated with its use. All statistical analyses were completed using SAS software (version 9.2). This study was exempt from review by the Human Subjects Committee of the University of Minnesota's Institutional Review Board because we used preexisting data void of any personal identifiers.
Methods

Database
Results
We identified 127,257 patients who met inclusion criteria during the study period.
On bivariate analysis we found significant differences between patients who received WBRT compared to patients who received IAPBI. Patients differed in age, race, stage of disease, and marital status. Women in the IAPBI treatment group were more likely to be older, widowed, and have stage I disease. Whites were the predominant race in both groups and African Americans were equally represented ( Table 1) . We also found We used logistic regression to evaluate several patient and tumor characteristics as predictors of the receipt of IAPBI therapy (vs. WBRT) while adjusting for potential confounders ( 
Conclusion
The rate of IAPBI therapy is increasing in the United States while the rate of WBRT is decreasing. IAPBI may be a favorable alternative to WBRT with a shorter course of therapy, acceptable cosmesis, and low complication rates. The follow-up data on recurrence rates, however, are still premature and cannot be adequately compared to traditional WBRT. Until the release of NSABP-B39/RTOG 0413, clinicians should be encouraged to enroll women in clinical trials and to avoid off-trial use of this therapy. 
